DK2186902T3 - Medicinske præparater til behandling af alfa-galactosidase A-mangel - Google Patents

Medicinske præparater til behandling af alfa-galactosidase A-mangel

Info

Publication number: DK2186902T3
Authority: DK; Denmark
Prior art keywords: gal; methods; galactosidase; medications; deficiency
Prior art date: 1999-03-11

Application number

DK10152432.0T

Other languages

English (en)

Inventor

Richard Selden

Marianne Borowski

Carol M Kinoshita

Douglas A Treco

Melanie D Williams

Thomas J Schuetz

Peter Francis Daniel

Original Assignee

Shire Human Genetic Therapies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-11

Filing date

2000-03-09

Publication date

2012-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2186902(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-09 Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies

2012-09-03 Application granted granted Critical

2012-09-03 Publication of DK2186902T3 publication Critical patent/DK2186902T3/da

Links

208000024720 Fabry Disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000002483 medication Methods 0.000 title 1
238000000034 method Methods 0.000 abstract 4
238000002360 preparation method Methods 0.000 abstract 4

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Toxicology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)

DK10152432.0T 1999-03-11 2000-03-09 Medicinske præparater til behandling af alfa-galactosidase A-mangel DK2186902T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/266,014 US6458574B1 (en)	1996-09-12	1999-03-11	Treatment of a α-galactosidase a deficiency
EP06025159A EP1820862A3 (en)	1999-03-11	2000-03-09	Medical preparations for the treatment of alpha-galactosidase a deficiency

Publications (1)

Publication Number	Publication Date
DK2186902T3 true DK2186902T3 (da)	2012-09-03

Family

ID=23012821

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK10180768.3T DK2314699T3 (da)	1999-03-11	2000-03-09	Lægemiddelpræparater til behandlingen af alfa-galactosidase-a mangel
DK00913825T DK1163349T3 (da)	1999-03-11	2000-03-09	Medicinske præparater til behandling af alfa-galactosidase A-mangel
DK10152432.0T DK2186902T3 (da)	1999-03-11	2000-03-09	Medicinske præparater til behandling af alfa-galactosidase A-mangel

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK10180768.3T DK2314699T3 (da)	1999-03-11	2000-03-09	Lægemiddelpræparater til behandlingen af alfa-galactosidase-a mangel
DK00913825T DK1163349T3 (da)	1999-03-11	2000-03-09	Medicinske præparater til behandling af alfa-galactosidase A-mangel

Country Status (22)

Country	Link
US (4)	US6458574B1 (da)
EP (6)	EP1820862A3 (da)
JP (6)	JP2002538183A (da)
KR (2)	KR100961740B1 (da)
CN (4)	CN103585621B (da)
AT (1)	ATE386808T1 (da)
AU (1)	AU3519400A (da)
CA (3)	CA2833396C (da)
CY (3)	CY1107951T1 (da)
DE (1)	DE60038104T2 (da)
DK (3)	DK2314699T3 (da)
ES (3)	ES2391221T3 (da)
HK (2)	HK1043386B (da)
HU (1)	HU228743B1 (da)
IL (2)	IL145381A0 (da)
MX (1)	MXPA01009222A (da)
NO (2)	NO329689B1 (da)
NZ (1)	NZ514077A (da)
PL (1)	PL210833B1 (da)
PT (3)	PT1163349E (da)
RU (1)	RU2248213C2 (da)
WO (1)	WO2000053730A2 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) *	2003-04-27	2003-11-23	Metabogal Ltd	Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) *	1996-09-26	2005-02-10	Metabogal Ltd.	Cell/tissue culturing device, system and method
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
EP1974752B1 (en) *	2001-04-30	2012-09-26	BioMarin Pharmaceutical Inc.	Subcellular targeting of therapeutic proteins
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US20040005309A1 (en) *	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
US20030072761A1 (en)	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
BR122017016940B8 (pt) *	2002-04-25	2021-07-27	Transkaryotic Therapies Inc	método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
US20060018882A1 (en) *	2004-06-21	2006-01-26	Kaemmerer William F	Medical devices and methods for delivering compositions to cells
PT2857036T (pt)	2003-01-31	2017-03-13	Mount Sinai School Of Medicine Of N Y Univ	Terapia combinada para o tratamento de distúrbios de deficiência proteica
US7422310B2 (en) *	2003-04-25	2008-09-09	Hewlett-Packard Development Company, L.P.	Methods and apparatus for selecting image enhancement techniques
US20100196345A1 (en) *	2003-04-27	2010-08-05	Protalix	Production of high mannose proteins in plant culture
US7951557B2 (en)	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
US7442372B2 (en)	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
CA2553955C (en)	2004-02-10	2012-08-28	Zystor Therapeutics, Inc.	Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) *	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
CN1308444C (zh) *	2005-04-15	2007-04-04	中国人民解放军军事医学科学院野战输血研究所	基因重组α－半乳糖苷酶大批量发酵液的纯化方法
AU2006247065B8 (en)	2005-05-17	2012-07-12	Amicus Therapeutics, Inc.	A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
US7935336B2 (en)	2005-11-18	2011-05-03	Tokyo Metropolitan Organization For Medical Research	Highly functional enzyme having α-galactosidase activity
WO2007086067A1 (en) *	2006-01-30	2007-08-02	Diagnostic Technologies Ltd.	Method for monitoring tocolytic treatment
CA2669347A1 (en) *	2006-11-13	2008-05-29	Zystor Therapeutics, Inc.	Methods for treating pompe disease
EP2150608B1 (en) *	2007-05-07	2017-11-29	Protalix Ltd.	Large scale disposable bioreactor
US20100291060A1 (en) *	2007-08-29	2010-11-18	Shire Human Genetic Therapies, Inc	Subcutaneous administration of alpha-galactosidase a
ES2629853T3 (es) *	2008-05-07	2017-08-16	Biomarin Pharmaceutical Inc.	Péptidos de dirección lisosómica y usos de los mismos
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
EP2475376B1 (en)	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
DK2865751T3 (da) *	2010-03-02	2017-01-09	Protalix Ltd	Stabiliseret alpha-galactosidase og anvendelser deraf
US20110293585A1 (en) *	2010-04-21	2011-12-01	Helix Therapeutics, Inc.	Compositions and methods for treatment of lysosomal storage disorders
PT3626736T (pt)	2010-07-08	2025-08-11	Takeda Pharmaceuticals Co	Método de produção de fvw recombinante de elevado peso molecular na cultura celular
WO2012051567A2 (en)	2010-10-15	2012-04-19	The Trustees Of Columbia University In The City Of New York	Obesity-related genes and their proteins and uses thereof
SI2635299T1 (sl)	2010-11-02	2020-02-28	The Trustees Of Columbia University In The City Of New York	Postopki za zdravljenje motenj izgube las
KR101906623B1 (ko) *	2011-03-04	2018-10-10	가부시키가이샤 도우사 고가쿠 겐큐쇼	시알산 함유 당쇄의 제조방법
PT2717893T (pt)	2011-06-08	2019-08-20	Translate Bio Inc	Composições de nanopartículas lipídicas e métodos para transferência de arnm
KR20230066482A (ko)	2012-03-07	2023-05-15	아미쿠스 세라퓨틱스, 인코포레이티드	폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US10039777B2 (en)	2012-03-20	2018-08-07	Neuro-Lm Sas	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
ES2694681T3 (es)	2012-03-29	2018-12-26	The Trustees Of Columbia University In The City Of New York	Métodos para tratar trastornos de pérdida capilar
HK1209625A1 (en) *	2012-07-17	2016-04-08	Amicus Therapeutics, Inc.	Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014016873A1 (en)	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) *	2012-07-26	2017-11-08	Ｊｃｒファーマ株式会社	組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014120900A1 (en) *	2013-01-31	2014-08-07	Icahn School Of Medicine At Mount Sinai	Enhanced therapeutic regimens for treating fabry disease
ES2680595T3 (es)	2013-03-14	2018-09-10	Translate Bio, Inc.	Evaluación cuantitativa para eficacia de ARN mensajero para tapar
EA201591286A1 (ru)	2013-03-14	2016-02-29	Шир Хьюман Дженетик Терапис, Инк.	Количественная оценка эффективности кэп матричной рнк
TWI642782B (zh) *	2013-10-23	2018-12-01	健臻公司	重組醣蛋白及其用途
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
CN106102749B (zh)	2014-03-05	2019-07-12	奥特吉尼克斯制药公司	唾液酸化糖蛋白组合物及其用途
CN114540327B (zh)	2014-09-30	2026-03-24	阿米库斯治疗学公司	具有增强的碳水化合物的高强度酸性α-葡糖苷酶
US20170360900A1 (en)	2014-12-22	2017-12-21	Codexis, Inc.	Human alpha-galactosidase variants
CA3225136A1 (en) *	2014-12-22	2016-06-30	Genzyme Corporation	Methods of culturing a mammalian cell
WO2016116966A1 (en)	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en)	2015-04-09	2018-05-29	Kinetiq, Inc.	Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
EP3347486A4 (en)	2015-09-09	2019-06-19	The Trustees of Columbia University in the City of New York	REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
KR102747683B1 (ko)	2015-12-30	2024-12-31	아미쿠스 세라퓨틱스, 인코포레이티드	폼페병 치료용의 강화된 산 알파-글루코시다제
EP3416976A2 (en)	2016-02-16	2018-12-26	Yale University	Compositions for enhancing targeted gene editing and methods of use thereof
SG11201808455VA (en)	2016-03-30	2018-10-30	Amicus Therapeutics Inc	Formulations comprising recombinant acid alpha-glucosidase
JP7046003B2 (ja) *	2016-03-30	2022-04-01	アミカスセラピューティックスインコーポレイテッド	高ｍ６ｐ組換えタンパク質の選択方法
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018071814A1 (en)	2016-10-14	2018-04-19	The Trustees Of Columbia University In The City Of New York	Methods of treating alcohol abuse disorder
CN110022904B (zh) *	2016-10-20	2024-04-19	桑格摩生物治疗股份有限公司	用于治疗法布里病的方法和组合物
TW201829770A (zh) *	2017-01-10	2018-08-16	美商阿米庫斯醫療股份有限公司	用於治療fabry氏病之重組α-半乳糖苷酶A
EA039750B1 (ru) *	2017-03-30	2022-03-10	Амикус Терапьютикс, Инк.	Способ отбора рекомбинантных белков с высоким содержанием m6p
US20200113821A1 (en)	2017-04-04	2020-04-16	Yale University	Compositions and methods for in utero delivery
ES2950808T3 (es)	2017-05-15	2023-10-13	Amicus Therapeutics Inc	Alfa-glucosidasa ácida humana recombinante
WO2020047282A1 (en) *	2018-08-29	2020-03-05	University Of Copenhagen	Lysosomal enzymes modified by cell based glycoengineering
MX2021007552A (es)	2018-12-20	2021-08-11	Codexis Inc	Variantes de alfa-galactosidasa humana.
JP7771045B2 (ja)	2019-07-09	2025-11-17	ジェネトン	糖原病（ｇｓｄ）の処置
TW202128264A (zh) *	2019-09-25	2021-08-01	瑞士商赫孚孟拉羅股份公司	使用經預測之溶離緩衝鹽濃度的陽離子層析法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5322158B2 (da) *	1974-05-02	1978-07-06
US4407957A (en)	1981-03-13	1983-10-04	Damon Corporation	Reversible microencapsulation of a core material
EP0159604B1 (en)	1984-04-09	1990-11-07	Toyo Boseki Kabushiki Kaisha	Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en)	1984-06-18	1988-08-16	Eli Lilly And Company	Method of inhibiting aromatase
GB8530631D0 (en) *	1985-12-12	1986-01-22	Ciba Geigy Ag	Thrombin inhibitors
US4764378A (en)	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
US5272066A (en) *	1986-03-07	1993-12-21	Massachusetts Institute Of Technology	Synthetic method for enhancing glycoprotein stability
EP0463109A4 (en)	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) *	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
US5382518A (en) *	1989-07-13	1995-01-17	Sanofi	Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
WO1991003556A1 (en) *	1989-09-05	1991-03-21	Biotechnology Australia Pty Ltd	Recombinant product
US5697901A (en) *	1989-12-14	1997-12-16	Elof Eriksson	Gene delivery by microneedle injection
US5661132A (en) *	1989-12-14	1997-08-26	Auragen, Inc.	Wound healing
US5401650A (en) *	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
US5356804A (en)	1990-10-24	1994-10-18	Mount Sinai School Of Medicine Of The City Of New York	Cloning and expression of biologically active human α-galactosidase A
SG47470A1 (en)	1991-04-25	1998-04-17	Univ Brown Res Found	Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
WO1993000951A1 (en)	1991-07-02	1993-01-21	Inhale, Inc.	Method and device for delivering aerosolized medicaments
US5750376A (en)	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5968502A (en)	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
PT101031B (pt)	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5858751A (en)	1992-03-09	1999-01-12	The Regents Of The University Of California	Compositions and methods for producing sialyltransferases
ES2105262T3 (es)	1992-05-18	1997-10-16	Minnesota Mining & Mfg	Dispositivo de suministro de farmaco a traves de las mucosas.
US5785049A (en)	1994-09-21	1998-07-28	Inhale Therapeutic Systems	Method and apparatus for dispersion of dry powder medicaments
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5804413A (en)	1992-07-31	1998-09-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Herpes simplex virus strains for gene transfer
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
ATE220327T1 (de)	1992-09-29	2002-07-15	Inhale Therapeutic Syst	Pulmonale abgabe von aktiven fragmenten des parathormons
US5389539A (en)	1992-11-30	1995-02-14	Massachusetts Institute Of Technology	Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en)	1993-08-30	2001-12-11	Hawaii Biotechnology Group, Inc.	DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) *	1993-09-23	1999-01-13	New England Biolabs Inc	INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de)	1993-11-20	1995-05-24	Beiersdorf Ag	Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en)	1993-12-28	1998-12-01	Becton Dickinson And Company	Molecules for iontophoretic delivery
US5789247A (en)	1994-04-01	1998-08-04	Ballay; Annick	Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr)	1994-04-06	1997-10-03	Defarges Alain Moreau	Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) *	1994-12-30	1998-11-10	Alko Group Ltd.	Methods of modifying carbohydrate moieties
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
AU4772596A (en) *	1995-01-30	1996-08-21	New York Blood Center, Inc., The	Recombinant alpha-galactosidase enzyme
US5780014A (en)	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en)	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
US6566089B1 (en) *	1996-09-04	2003-05-20	Tularik Inc.	Cell-based drug screens for regulators of gene expression
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
PT1538202E (pt)	1996-09-13	2014-04-22	Shire Human Genetic Therapies	Produção de alga-galactosidase a humana
IL125423A (en) *	1998-07-20	2004-08-31	Israel State	Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) *	2001-08-31	2004-06-15	Clearant, Inc.	Methods for sterilizing preparations of digestive enzymes

1999
- 1999-03-11 US US09/266,014 patent/US6458574B1/en not_active Expired - Lifetime
2000
- 2000-03-09 NZ NZ514077A patent/NZ514077A/xx not_active IP Right Cessation
- 2000-03-09 CA CA2833396A patent/CA2833396C/en not_active Expired - Lifetime
- 2000-03-09 AT AT00913825T patent/ATE386808T1/de active
- 2000-03-09 KR KR1020077019031A patent/KR100961740B1/ko not_active Expired - Lifetime
- 2000-03-09 MX MXPA01009222A patent/MXPA01009222A/es active IP Right Grant
- 2000-03-09 KR KR1020017011552A patent/KR100892334B1/ko not_active Expired - Lifetime
- 2000-03-09 CN CN201310243356.3A patent/CN103585621B/zh not_active Expired - Lifetime
- 2000-03-09 ES ES10152432T patent/ES2391221T3/es not_active Expired - Lifetime
- 2000-03-09 AU AU35194/00A patent/AU3519400A/en not_active Abandoned
- 2000-03-09 RU RU2001127533/15A patent/RU2248213C2/ru active
- 2000-03-09 CN CNA2007101482923A patent/CN101219213A/zh not_active Withdrawn
- 2000-03-09 PL PL350658A patent/PL210833B1/pl unknown
- 2000-03-09 DK DK10180768.3T patent/DK2314699T3/da active
- 2000-03-09 JP JP2000603353A patent/JP2002538183A/ja active Pending
- 2000-03-09 CA CA3012663A patent/CA3012663A1/en not_active Expired - Lifetime
- 2000-03-09 ES ES00913825T patent/ES2300256T3/es not_active Expired - Lifetime
- 2000-03-09 EP EP06025159A patent/EP1820862A3/en not_active Ceased
- 2000-03-09 EP EP17169335.1A patent/EP3231871A1/en not_active Withdrawn
- 2000-03-09 CN CN201610478912.9A patent/CN106110309A/zh active Pending
- 2000-03-09 DK DK00913825T patent/DK1163349T3/da active
- 2000-03-09 WO PCT/US2000/006118 patent/WO2000053730A2/en not_active Ceased
- 2000-03-09 EP EP10152432A patent/EP2186902B1/en not_active Revoked
- 2000-03-09 PT PT00913825T patent/PT1163349E/pt unknown
- 2000-03-09 EP EP10180768.3A patent/EP2314699B1/en not_active Expired - Lifetime
- 2000-03-09 CA CA002365923A patent/CA2365923A1/en active Pending
- 2000-03-09 ES ES10180768.3T patent/ES2634317T3/es not_active Expired - Lifetime
- 2000-03-09 DE DE60038104T patent/DE60038104T2/de not_active Expired - Lifetime
- 2000-03-09 DK DK10152432.0T patent/DK2186902T3/da active
- 2000-03-09 PT PT10152432T patent/PT2186902E/pt unknown
- 2000-03-09 HU HU0200467A patent/HU228743B1/hu unknown
- 2000-03-09 PT PT101807683T patent/PT2314699T/pt unknown
- 2000-03-09 IL IL14538100A patent/IL145381A0/xx unknown
- 2000-03-09 EP EP10180757A patent/EP2287319A1/en not_active Withdrawn
- 2000-03-09 EP EP00913825A patent/EP1163349B1/en not_active Expired - Lifetime
- 2000-03-09 HK HK02104366.6A patent/HK1043386B/en not_active IP Right Cessation
- 2000-03-09 CN CNB008073120A patent/CN100417727C/zh not_active Expired - Lifetime
2001
- 2001-09-11 NO NO20014415A patent/NO329689B1/no not_active IP Right Cessation
- 2001-09-11 IL IL145381A patent/IL145381A/en not_active IP Right Cessation
2002
- 2002-06-07 US US10/165,060 patent/US20030077806A1/en not_active Abandoned
- 2002-06-10 US US10/165,968 patent/US20030113894A1/en not_active Abandoned
2008
- 2008-05-20 CY CY20081100521T patent/CY1107951T1/el unknown
2010
- 2010-09-27 JP JP2010215000A patent/JP5615648B2/ja not_active Expired - Lifetime
- 2010-10-22 NO NO20101493A patent/NO20101493L/no not_active Application Discontinuation
- 2010-11-11 US US12/944,688 patent/US20110280856A1/en not_active Abandoned
2012
- 2012-08-10 CY CY20121100736T patent/CY1113051T1/el unknown
2013
- 2013-08-26 JP JP2013174418A patent/JP5899169B2/ja not_active Expired - Lifetime
2014
- 2014-12-16 JP JP2014254079A patent/JP6081980B2/ja not_active Expired - Lifetime
2016
- 2016-10-12 JP JP2016200833A patent/JP6346236B2/ja not_active Expired - Lifetime
2017
- 2017-07-26 CY CY20171100801T patent/CY1119369T1/el unknown
- 2017-11-15 JP JP2017219734A patent/JP6626071B2/ja not_active Expired - Lifetime
2018
- 2018-04-03 HK HK18104453.2A patent/HK1245320A1/en unknown

Also Published As

Publication number	Publication date
CA2833396A1 (en)	2000-09-14
HUP0200467A3 (en)	2006-06-28
CA3012663A1 (en)	2000-09-14
CN1354796A (zh)	2002-06-19
US20110280856A1 (en)	2011-11-17
JP2018038423A (ja)	2018-03-15
JP5899169B2 (ja)	2016-04-06
US20030113894A1 (en)	2003-06-19
IL145381A0 (en)	2002-06-30
JP2011037867A (ja)	2011-02-24
AU3519400A (en)	2000-09-28
EP2186902A3 (en)	2010-09-01
HU228743B1 (en)	2013-05-28
JP6626071B2 (ja)	2019-12-25
ES2300256T3 (es)	2008-06-16
US6458574B1 (en)	2002-10-01
KR20020021371A (ko)	2002-03-20
EP2314699B1 (en)	2017-05-31
CA2833396C (en)	2018-08-28
EP3231871A1 (en)	2017-10-18
KR100961740B1 (ko)	2010-06-07
KR100892334B1 (ko)	2009-04-08
CN103585621B (zh)	2016-08-10
JP6346236B2 (ja)	2018-06-20
KR20070090277A (ko)	2007-09-05
DE60038104D1 (de)	2008-04-03
ES2634317T3 (es)	2017-09-27
EP2287319A1 (en)	2011-02-23
JP6081980B2 (ja)	2017-02-15
HK1245320A1 (en)	2018-08-24
HK1043386A1 (en)	2002-09-13
CN100417727C (zh)	2008-09-10
EP1163349A2 (en)	2001-12-19
NZ514077A (en)	2004-02-27
CN101219213A (zh)	2008-07-16
WO2000053730A3 (en)	2001-03-15
PT1163349E (pt)	2008-05-19
NO20014415D0 (no)	2001-09-11
EP1820862A3 (en)	2007-10-31
EP1820862A2 (en)	2007-08-22
EP1163349B1 (en)	2008-02-20
EP2186902A2 (en)	2010-05-19
JP2017014279A (ja)	2017-01-19
PT2186902E (pt)	2012-08-28
JP2013241466A (ja)	2013-12-05
EP2314699A1 (en)	2011-04-27
CY1119369T1 (el)	2018-02-14
NO329689B1 (no)	2010-11-29
JP2015091834A (ja)	2015-05-14
CY1107951T1 (el)	2013-09-04
ES2391221T3 (es)	2012-11-22
CN103585621A (zh)	2014-02-19
CN106110309A (zh)	2016-11-16
US20030077806A1 (en)	2003-04-24
CY1113051T1 (el)	2016-04-13
WO2000053730A9 (en)	2001-10-11
CA2365923A1 (en)	2000-09-14
WO2000053730A2 (en)	2000-09-14
DK2314699T3 (da)	2017-08-07
PL210833B1 (pl)	2012-03-30
EP2186902B1 (en)	2012-05-23
PT2314699T (pt)	2017-08-01
IL145381A (en)	2009-12-24
HUP0200467A2 (en)	2002-06-29
DE60038104T2 (de)	2009-02-12
NO20101493L (no)	2001-11-12
PL350658A1 (en)	2003-01-27
NO20014415L (no)	2001-11-12
RU2248213C2 (ru)	2005-03-20
JP5615648B2 (ja)	2014-10-29
DK1163349T3 (da)	2008-06-23
HK1043386B (en)	2008-06-13
MXPA01009222A (es)	2002-06-04
JP2002538183A (ja)	2002-11-12
HK1143833A1 (en)	2011-01-14
ATE386808T1 (de)	2008-03-15

Publication	Publication Date	Title
DK1163349T3 (da)	2008-06-23	Medicinske præparater til behandling af alfa-galactosidase A-mangel
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
TR199800012T1 (xx)	1998-04-21	Piroloprimidinler ve preparasyon i�in tatbikler.
CY1108706T1 (el)	2014-04-09	Ανοσορυθμιστης
NO971889L (no)	1997-06-23	Forbindelser og sammensetninger for levering av aktive midler
BR9806752A (pt)	2000-03-14	Ftalazinonas.
NO873298L (no)	1988-02-08	Oralt terapeutisk system med systematisk virkning.
DK0973735T3 (da)	2003-06-23	Polyaromatiske antivirale præparater
DK1003546T3 (da)	2006-10-30	Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
TR199901949T2 (xx)	2000-01-21	Lemfositik t�m�rler i�in �areler.
DK0725637T3 (da)	2001-03-26	Parenteralt busulfan til behandling af malign sygdom
NO972391D0 (no)	1997-05-26	2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE249835T1 (de)	2003-10-15	Immunoregulator
EA199900633A1 (ru)	2000-02-28	Способы терапевтического введения анти-cd40l соединений
ATE188873T1 (de)	2000-02-15	Tris-platin-komplexe
TR200001486T2 (tr)	2001-07-23	Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
AU8239298A (en)	1999-02-08	Nucleotide-comprising composition
TR200001102T2 (tr)	2000-08-21	İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE60222383D1 (de)	2007-10-25	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
DE69414194D1 (de)	1998-12-03	Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
NO20020914L (no)	2002-04-26	Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
EA200000163A1 (ru)	2000-10-30	Противоопухолевое средство
ATE356144T1 (de)	2007-03-15	Regulatorische/entfaltende peptide von ezrin
BR9812002A (pt)	2000-09-26	Compostos com efeito antiprimeiro-passe
IT8720800A0 (it)	1987-06-05	Composto attivo nella terapia carciovascolare.